Recent Winners


+180%
PLX
Alert Price: $0.36
High Price: $1.01
Results: 180% in 40 Days
+157%
OREX
Alert Price: $1.81
High Price: $4.65
Results: 157% in 36 Days
+133%
CGIX
Alert Price: $1.50
High Price: $3.50
Results: 133% in 85 Days
+91%
GBT
Alert Price: $15.85
High Price: $30
Results: 91% in 41 Days
+90%
LPTH
Alert Price: $1.40
High Price: $2.66
Results: 90% in 69 Days
+87%
ARIA
Alert Price: $12.72
High Price: $23.75
Results: 87% in 20 Days
+72%
TRR
Alert Price: $10.10
High Price: $17.38
Results: 72% in 51 Days
+64%
MBLY
Alert Price: $37.68
High Price: $61.73
Results: 64% in 67 Days
+58%
AAOI
Alert Price: $28.22
High Price: $44.46
Results: 58% in 60 Days
+58%
XGTI
Alert Price: $1.47
High Price: $2.32
Results: 58% in 29 Days
+55%
EXAS
Alert Price: $15.10
High Price: $23.40
Results: 55% in 37 Days
+47%
CPRX
Alert Price: $1.20
High Price: $1.76
Results: 47% in 60 Days
+45%
PTLA
Alert Price: $25.06
High Price: $36.40
Results: 45% in 67 Days
+44%
VRTX
Alert Price: $79.39
High Price: $114.06
Results: 44% in 51 Days
+38%
EDIT
Alert Price: $18.24
High Price: $25.09
Results: 38% in 55 Days
+36%
CYNO
Alert Price: $48.25
High Price: $65.90
Results: 36% in 28 Days
+35%
NKTR
Alert Price: $13.75
High Price: $18.50
Results: 35% in 51 Days
+32%
EBS
Alert Price: $27.22
High Price: $35.88
Results: 32% in 6 Days
+31%
ATVI
Alert Price: $37.05
High Price: $48.42
Results: 31% in 68 Days
+27%
ILMN
Alert Price: $134.56
High Price: $171.52
Results: 27% in 55 Days
+27%
ICHR
Alert Price: $13.40
High Price: $17.04
Results: 27% in 22 Days
+27%
QRVO
Alert Price: $55.67
High Price: $70.64
Results: 27% in 73 Days
+25%
WILN
Alert Price: $1.58
High Price: $1.98
Results: 25% in 72 Days
+25%
BMA
Alert Price: $70.05
High Price: $87.41
Results: 25% in 61 Days
+23%
CNAT
Alert Price: $4.43
High Price: $5.45
Results: 23% in 3 Days
+23%
PEIX
Alert Price: $8.30
High Price: $10.25
Results: 23% in 12 Days
+21%
KATE
Alert Price: $15.40
High Price: $18.67
Results: 21% in 11 Days
+20%
REPH
Alert Price: $6.89
High Price: $8.25
Results: 20% in 11 Days
+20%
GNRT
Alert Price: $4.49
High Price: $5.37
Results: 20% in 62 Days
+20%
SN
Alert Price: $11.24
High Price: $13.46
Results: 20% in 15 Days
+20%
DXCM
Alert Price: $63.23
High Price: $76.06
Results: 20% in 68 Days

Past results are not indicative of future profits. This table is accurate, though not every trade is represented.

jb-vertical


biotech-breakouts2

Trading Lessons

Mainstream Financial News

Archives

Follow Us on StockTwits

Sell Cancer Genetics For an Awesome 133% Win!

April 16, 2017: Sell Cancer Genetics for an incredible 133% win in 85 days and congratulations if you made money on the trade.

December 9, 2016: H.C. Wainwright/ Rodman & Renshaw reiterates a Buy rating on Cancer Genetics, and sets a price target of $6.

December 7, 2016: Cancer Genetics announced a collaboration with BeiGene, a global, clinical-stage, research-based biopharmaceutical company developing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer. The two companies will work together on BeiGenes immune marker and genomics initiatives to accelerate studies of tumor microenvironment in cancer patients, which will aid in drug target identification and biomarker discovery.

BeiGenes clinical-stage drug candidates inhibit four major oncology targets, including Brutons tyrosine kinase (BGB-3111), the immune checkpoint receptor PD-1 (BGB-A317), the PARP family of proteins (BGB-290), and the RAF dimer protein complex (BGB-283). Each of BeiGenes drug candidates has demonstrated promising early anti-tumor activity and a favorable safety profile and has the potential to be a best-in-class or first-in-class product. These drug candidates are being evaluated as monotherapies and in combination regimens for the treatment of a variety of cancers, including solid tumors and hematological malignancies. CGI will provide biomarker and central laboratory for multiple clinical trials for BeiGenes BGB-3111, BGB-A317, and BGB-290 programs to promote accelerated market entrance and identify subsets of patient populations.

December 5, 2016: Cancer Genetics announces it is on Merck’s list of national reference laboratories offering the PD-L1 22C3 pharmDx immunohistochemistry (IHC) assay, the first U.S. Food and Drug Administration (FDA)-approved companion diagnostic test for pembrolizumab, KEYTRUDA, for PD-L1 testing in non-small cell lung cancer (NSCLC). The company first started offering the DAKO PD-L1 IHC 22C3 pharmDx test in early 2016 and was recently listed as a national reference laboratory.

Cancer Genetics now offers all the available FDA approved companion diagnostics for PD-L1 testing across several cancer indications and is providing these tests for both patient management in the clinical setting as well as for immuno-oncology trials sponsored by leading pharmaceutical companies. Cancer Genetics is now supporting over 100 clinical studies and trials, and over 30 with a component for immuno-oncology testing and monitoring.

Cancer Genetics Stock Chart


The Finviz screener settings used to find Cancer Genetics are: Sector Healthcare, EPS growth next year Over 30%, EPS growth past 5 years Over 30%, Sales growth past 5 years Over 30%, Sales growth qtr over qtr Over 30%

Cancer Genetics, Inc. offerers diagnostic products and services that enable precision medicine in the field of oncology. Products and services being developed at CGI are poised to transform cancer patient management, increase treatment efficacy, and reduce healthcare costs. CGI’s cutting-edge proprietary tests and state-of-the-art reference laboratory provide critical genomic information where patients and their physicians need it most – to diagnose, monitor and inform cancer treatment.

Trading The News: Cancer Genetics In The News